CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...
Zacks Investment Research on MSN
Why CRISPR Therapeutics AG (CRSP) outpaced the stock market today
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.
CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...
CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient ...
We expect CRISPR Therapeutics CRSP to surpass expectations when it reports fourth-quarter and full-year 2025 results. The company’s earnings beat estimates by 11.36% in the last reported quarter. The ...
Zacks.com on MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) closed at $47.69 in the latest trading session, marking a -4.79% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Elsewhere ...
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results